The hardware and bandwidth for this mirror is donated by dogado GmbH, the Webhosting and Full Service-Cloud Provider. Check out our Wordpress Tutorial.
If you wish to report a bug, or if you are interested in having us mirror your free-software or open-source project, please feel free to contact us at mirror[@]dogado.de.

trialfigs

Efficacy and safety graphics for a clinical review package, organised by therapeutic area.

This is an independent R package. It is not an FDA product and not a guarantee that a figure will be accepted. Reference lines follow RECIST 1.1 and the FDA drug-induced liver injury guidance. Data from the simulators are synthetic.

Suggested GitHub repository name: trialfigs. R package name: trialfigs.

Install

# Once the repository exists:
install.packages("remotes")
remotes::install_github("YOURUSER/trialfigs")
library(trialfigs)

From a local checkout:

install.packages(c("ggplot2", "survival"))
install.packages(".", repos = NULL, type = "source")

What to plot, by therapeutic area

ta_plot_catalog() returns this map. The function column is what the example scripts call.

Therapeutic area	Display reviewers expect	Function
Oncology	Kaplan–Meier of overall survival and progression-free survival, with censoring ticks and number at risk	`plot_km`
Oncology	Waterfall of best percent change in sum of diameters. Dashed lines at −30% and +20% (RECIST 1.1)	`plot_waterfall`
Oncology	Swimmer plot: time on treatment, objective response, progression	`plot_swimmer`
Oncology	Spider plot: individual tumor trajectories plus the arm mean	`plot_spider`
Oncology	Objective response rate with a Wilson interval	`plot_responder`
Oncology	Forest of hazard ratios by prespecified subgroup	`plot_forest`, `cox_hr`
Cardiovascular	Kaplan–Meier of time to first MACE. State the competing-risk limitation if non-CV death is common	`plot_km`
Cardiovascular	Forest of hazard ratios, overall and by subgroup	`plot_forest`
Cardiovascular	Mean change in SBP or LDL-C with a 95% interval	`plot_change`
Endocrinology	Mean change in HbA1c	`plot_change`
Endocrinology	Responder rate, for example HbA1c < 7% at the landmark visit	`plot_responder`
Immunology	Mean change in DAS28, PASI, or CDAI	`plot_change`
Immunology	Binary responder (ACR20, PASI75, DAS28 improvement)	`plot_responder`
Infectious disease	Mean change in log10 viral load	`plot_change`
Infectious disease	Time to virologic clearance	`plot_km`
Neuroscience	Mean change in MADRS, ADAS-Cog, or UPDRS	`plot_change`
Neuroscience	Landmark responder, for example 50% MADRS reduction	`plot_responder`
Safety, all areas	Adverse-event incidence dot plot with Wilson intervals, ordered by risk difference	`plot_ae`
Safety, all areas	eDISH: peak ALT × ULN vs peak total bilirubin × ULN. Quadrant is ALT ≥ 3× and bilirubin ≥ 2×	`plot_edish`
Safety, all areas	Baseline vs post-baseline maximum laboratory value	`plot_lab_shift`
Safety, all areas	Exposure: treatment duration by arm	`plot_exposure`

Primary contrasts in a real submission should come from the model named in the SAP (Cox, MMRM, negative binomial). The intervals in plot_change are mean ± 1.96 SE, labelled as such, so they are not silently substituted for an MMRM LS-mean.

Real example

Data below are simulated. Do not describe them as trial results.

library(trialfigs)

onc <- simulate_oncology(n_per_arm = 80)

plot_km(
  onc$adsl,
  time = "os_months", event = "os_event", arm = "arm",
  title = "Overall survival",
  xlab = "Months", ylab = "Overall survival"
)

plot_waterfall(onc$adsl)
plot_swimmer(onc$adsl, max_n = 24)
plot_spider(onc$adtr)

forest <- rbind(
  cox_hr(onc$adsl, "os_months", "os_event", "arm", subgroup = "Overall"),
  cox_hr(onc$adsl[onc$adsl$sex == "F", ], "os_months", "os_event", "arm", subgroup = "Female"),
  cox_hr(onc$adsl[onc$adsl$sex == "M", ], "os_months", "os_event", "arm", subgroup = "Male")
)
plot_forest(forest, n = "n", title = "Overall survival by subgroup")

saf <- simulate_safety()
plot_ae(saf$adae, denom = saf$adsl, reference = "Placebo")
plot_edish(saf$adlb)
plot_exposure(saf$adsl)

Build the full gallery from the package root:

source("inst/examples/run_all.R")
# PNGs land in inst/examples/figures/

Script	Area	Figures
`inst/examples/01_oncology.R`	Oncology	OS, PFS, waterfall, swimmer, spider, forest, ORR
`inst/examples/02_cardiovascular.R`	Cardiovascular	MACE, subgroup forest, SBP change
`inst/examples/03_endocrinology.R`	Endocrinology	HbA1c change, HbA1c < 7%
`inst/examples/04_immunology.R`	Immunology	DAS28 change, DAS28 responder
`inst/examples/05_infectious.R`	Infectious disease	Viral-load change, time to clearance
`inst/examples/06_neuroscience.R`	Neuroscience	MADRS change, 50% responder
`inst/examples/07_safety.R`	Safety, all areas	AE dot plot, eDISH, ALT shift, exposure

Repository layout

trialfigs/
  DESCRIPTION              package metadata
  NAMESPACE                exports
  LICENSE                  MIT
  README.md
  NEWS.md
  trialfigs.Rproj
  .Rbuildignore
  .gitignore
  .github/workflows/R-CMD-check.yaml
  R/theme.R                palette, theme, catalog
  R/simulate.R             one simulator per therapeutic area
  R/plots_efficacy.R       KM, waterfall, swimmer, spider, forest, change, responder
  R/plots_safety.R         AE, eDISH, lab shift, exposure
  man/trialfigs-package.Rd
  inst/examples/           runnable review-style scripts

Put it on GitHub

cd trialfigs
git init
git add .
git commit -m "Initial trialfigs package"
gh repo create trialfigs --public --source=. --remote=origin --push

Replace YOURUSER in DESCRIPTION and in the install snippet above.

Conventions worth keeping

Population in the caption (ITT, safety, virologic), not only in a footnote nobody reads.
Number at risk on every Kaplan–Meier. Censoring ticks on.
RECIST lines only on tumor-burden plots, and only if the endpoint is RECIST.
eDISH quadrant cases get a narrative. Alkaline phosphatase and an alternative cause still have to be checked before anyone writes “Hy’s law”.
Subgroup forests are descriptive unless the subgroup was prespecified and the multiplicity plan says otherwise.
Do not invent a p-value the SAP did not specify.

References the figures follow

Eisenhauer EA et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009.
FDA. Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 2009. eDISH and Hy’s law quadrant.
PHUSE. Analysis and Displays Associated with Adverse Events, and the safety-topics white papers.
ICH E3. Structure and Content of Clinical Study Reports.

These binaries (installable software) and packages are in development.
They may not be fully stable and should be used with caution. We make no claims about them.
Health stats visible at Monitor.